TY - JOUR
AU - Nakagomi, Daiki
AB - Rheumatology, 2025, 64, 1548–1549 https://doi.org/10.1093/rheumatology/keae552 Advance access publication 14 October 2024 Rheumatology Letter to the Editor Letter to the Editor (Case report) Improvement of proteinuria by upadacitinib in a patient with refractory lupus membranous nephropathy 1, 1 1 1 1 Shunichiro Hanai , Yoshiaki Kobayashi , Moe Watanabe , Kojiro Ikeda , Soichiro Kubota , Daiki Nakagomi Department of Rheumatology, University of Yamanashi Hospital, Shimokato, Chuo-shi, Yamanashi, Japan Correspondence to: Shunichiro Hanai, Department of Rheumatology, University of Yamanashi Hospital, 1110 Shimokato, Chuo-shi, Yamanashi 409-3898, Japan. E-mail: shanai@yamanashi.ac.jp difficult because of mild proteinuria, polyarthritis and throm- Rheumatology key message bocytopenia. Belimumab was switched to intravenous anifro- Upadacitinib could be a promising therapy for lupus lumab and tapering of prednisolone was again attempted. membranous nephropathy UPCR increased with a prednisolone dose of 6 mg/day (UPCR: 3.0–8.7 g/gCr) and arthritis recurred. Although rit- uximab was a therapeutic option for LMN, JAK inhibitors were considered for their effects on articular involvements based on clinical trials [4], and our patient preferred oral DEAR EDITOR, LN is a major organ involvement of SLE. medications. Anifrolumab was then switched to upadacitinib Lupus membranous nephropathy (LMN) is observed in 10– at 15 mg/day (Fig. 1). Laboratory findings 
TI - Improvement of proteinuria by upadacitinib in a patient with refractory lupus membranous nephropathy
JF - Rheumatology
DO - 10.1093/rheumatology/keae552
DA - 2024-10-14
UR - https://www.deepdyve.com/lp/oxford-university-press/improvement-of-proteinuria-by-upadacitinib-in-a-patient-with-yeU1H9SXRF
SP - 1548
EP - 1549
VL - 64
IS - 3
DP - DeepDyve
ER -